GNPX News and Press, Genprex Inc. From 04/24/23

2023-04-24 08:20:02 ET Presto Automation ( PRST ) -16% . Jayud Global Logistics Limited ( JYD ) -14% . Wang & Lee Group ( WLGS ) -13% . Satixfy Communications ( SATX ) -10% . Onconova Therapeutics ( ONTX ) -9% . C3.ai ( AI ...

2023-04-19 15:29:56 ET In the vast landscape of investment opportunities, penny stocks have emerged as an alluring option for those seeking high-risk, high-reward ventures. These low-priced stocks, particularly those under $1, offer the potential for exponential gains alongside the inhe...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its research collaborators presented positive preclinical data for the NPRL2 gene (also known as the TUSC4 gene). According to ...

Genprex Collaborators Report Positive Preclinical Data With NPRL2 Gene Therapy Utilizing Non-Viral ONCOPREX® Nanoparticle Delivery System in Non-Small Cell Lung Cancer at the 2023 AACR Annual Meeting PR Newswire NPRL2 Gene Therapy Induces Effective Anti-Tumor Activity in ...

AUSTIN, TX / ACCESSWIRE / April 19, 2023 / On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide. To make matters worse, epidemiologic evidence suggests that people with diabetes - especially Type 2 diabetes - ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that unaffiliated, independent researchers recently presented preclinical data on the tumor suppressor gene, TUSC2, reporting that i...

Independent Researchers Find That TUSC2, the Gene Delivered by Genprex's REQORSA®, Functions as a Novel Tumor Suppressor for Glioblastoma PR Newswire Pre-clinical Study results show TUSC2 overexpression reduces colony formation, neurosphere formation and promotes apoptosi...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, is commending the U.S. Food and Drug Administration (“FDA”) and the organization’s recent initiative, which is designed to exped...

Genprex CEO Commends FDA's Initiative to Accelerate Approval Process for Gene Therapies PR Newswire Genprex is advancing its novel gene therapies for large patient populations with cancer and diabetes who currently have limited treatment options AUSTIN, Texas , ...

Genprex (NASDAQ: GNPX) , a clinical-stage gene therapy company focused on developing life-changing treatments for patients with cancer and diabetes, today announced that its Chief Manufacturing and Technology Officer Hemant Kumar, Ph.D. will participate in the upcoming Bioprocessing Summit Europe...